Literature DB >> 22278839

Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays.

P Pancholi1, C Kelly, M Raczkowski, J M Balada-Llasat.   

Abstract

Clostridium difficile is the most important cause of nosocomial diarrhea. Several laboratory techniques are available to detect C. difficile toxins or the genes that encode them in fecal samples. We evaluated the Xpert C. difficile and Xpert C. difficile/Epi (Cepheid, CA) that detect the toxin B gene (tcdB) and tcdB, cdt, and a deletion in tcdC associated with the 027/NAP1/BI strain, respectively, by real-time PCR, and the Illumigene C. difficile (Meridian Bioscience, Inc.) that detects the toxin A gene (tcdA) by loop-mediated isothermal amplification in stool specimens. Toxigenic culture was used as the reference method for discrepant stool specimens. Two hundred prospective and fifty retrospective diarrheal stool specimens were tested simultaneously by the cell cytotoxin neutralization assay (CCNA) and the Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. Of the 200 prospective stools tested, 10.5% (n = 23) were determined to be positive by CCNA, 17.5% (n = 35) were determined to be positive by Illumigene C. difficile, and 21.5% (n = 43) were determined to be positive by Xpert C. difficile and Xpert C. difficile/Epi. Of the 50 retrospective stools, previously determined to be positive by CCNA, 94% (n = 47) were determined to be positive by Illumigene C. difficile and 100% (n = 50) were determined to be positive by Xpert C. difficile and Xpert C. difficile/Epi. Of the 11 discrepant results (i.e., negative by Illumigene C. difficile but positive by Xpert C. difficile and Xpert C. difficile/Epi), all were determined to be positive by the toxigenic culture. A total of 21% of the isolates were presumptively identified by the Xpert C. difficile/Epi as the 027/NAP1/BI strain. The Xpert C. difficile and Xpert C. difficile/Epi assays were the most sensitive, rapid, and easy-to use assays for the detection of toxigenic C. difficile in stool specimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278839      PMCID: PMC3318532          DOI: 10.1128/JCM.06597-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

Review 1.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

2.  Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Authors:  Stéphanie Sirard; Louis Valiquette; Louis-Charles Fortier
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

3.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

Review 4.  Clostridium difficile associated diarrhoea: diagnosis and treatment.

Authors:  John Starr
Journal:  BMJ       Date:  2005-09-03

5.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

6.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

7.  Rapid and simple method for detecting the toxin B gene of Clostridium difficile in stool specimens by loop-mediated isothermal amplification.

Authors:  Haru Kato; Toshiyuki Yokoyama; Hideaki Kato; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

8.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens.

Authors:  C S Merz; C Kramer; M Forman; L Gluck; K Mills; K Senft; I Steiman; N Wallace; P Charache
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

10.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.

Authors:  L Clifford McDonald; Maria Owings; Daniel B Jernigan
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

View more
  37 in total

1.  Comparison of GenomEra C. difficile and Xpert C. difficile as confirmatory tests in a multistep algorithm for diagnosis of Clostridium difficile infection.

Authors:  Luis Alcalá; Elena Reigadas; Mercedes Marín; Antonia Fernández-Chico; Pilar Catalán; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.

Authors:  Bin Huang; Dazhi Jin; Jing Zhang; Janet Y Sun; Xiaobo Wang; Jeffrey Stiles; Xiao Xu; Mini Kamboj; N Esther Babady; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

3.  Comparison of BD GeneOhm Cdiff and Seegene Seeplex ACE PCR assays using toxigenic Clostridium difficile culture for direct detection of tcdB from stool specimens.

Authors:  Bo-Moon Shin; Se Jin Mun; Soo Jin Yoo; Eun Young Kuak
Journal:  J Clin Microbiol       Date:  2012-09-05       Impact factor: 5.948

4.  Reply to "Comparison of detection methods for Clostridium difficile".

Authors:  P Pancholi; C Kelly; M Raczkowski; J M Balada-Llasat
Journal:  J Clin Microbiol       Date:  2013-05       Impact factor: 5.948

5.  Comparison of detection methods for Clostridium difficile.

Authors:  Monica Ianosi-Irimie; Dawn Morong; Catherine Dragoni; Stanley Schofield
Journal:  J Clin Microbiol       Date:  2013-05       Impact factor: 5.948

Review 6.  Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  J Clin Microbiol       Date:  2015-10-28       Impact factor: 5.948

7.  Novel portable platform for molecular detection of toxigenic Clostridium difficile in faeces: a diagnostic accuracy study.

Authors:  J J Hirvonen; P Matero; C Siebert; J Kauppila; R Vuento; H Tuokko; S Boisset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-17       Impact factor: 3.267

Review 8.  Emerging technologies for the clinical microbiology laboratory.

Authors:  Blake W Buchan; Nathan A Ledeboer
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

9.  Rapid, label-free genetic detection of enteropathogens in stool without genetic isolation or amplification.

Authors:  Song Han; Mehmet C Soylu; Ceyhun E Kirimli; Wei Wu; Bhaswati Sen; Suresh G Joshi; Christopher L Emery; Giang Au; Xiaomin Niu; Richard Hamilton; Kyle Krevolin; Wei-Heng Shih; Wan Y Shih
Journal:  Biosens Bioelectron       Date:  2019-01-21       Impact factor: 10.618

10.  Evaluation of Clostridium difficile fecal load and limit of detection during a prospective comparison of two molecular tests, the illumigene C. difficile and Xpert C. difficile/Epi tests.

Authors:  Clare E Gyorke; Susan Wang; Jhansi L Leslie; Stuart H Cohen; Jay V Solnick; Christopher R Polage
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.